The Autism Spectrum Disorders (ASD) Market Is Projected To Reach $4.53 Billion By 2026 - Seite 3

Other recent developments in the healthcare markets include:

Synlogic, Inc. (NASDAQ: SYBX) recently announced the Company will release its first quarter 2021 financial results before the market opens on Thursday, May 13, 2021. The press release will be followed by a conference call at 8:30 am ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.

The conference call dial-in numbers are [phone] for domestic callers and [phone] for international callers. The conference ID number for the call is 2526209. Participants may access the live webcast via a link on the Synlogic website in the Events Calendar of the Investors and Media section. For those unable to participate in the conference call or webcast, a replay will be available for 30 days on the Company's website.

Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, recently reported financial results for the first quarter ended March 31, 2021, and recent corporate highlights.

"Our commercial execution is effectively raising awareness of GOCOVRI and its expanded label, enabling more patients, caregivers and physicians to make GOCOVRI their treatment of choice in Parkinson's related motor complications," said Neil F. McFarlane, Chief Executive Officer. "We are also delighted to expand our commercial footprint beyond Parkinson's disease, leveraging OSMOLEX ER to benefit patients with drug-induced extrapyramidal reactions. Despite continued market disruption, the growth of our products and our strong cash position gives us confidence in our ability to deliver long-term shareholder value."

MannKind Corporation (NASDAQ: MNKD) and United Therapeutics (Nasdaq: UTHR) reached a milestone recently in the development of Tyvaso DPI as United Therapeutics submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA). "The NDA submitted today by United Therapeutics builds upon a drug master file previously submitted by MannKind," said Michael Castagna, CEO of MannKind Corporation. "We are excited to see the second compound formulated with our technology complete a rigorous clinical development program. If approved by the FDA, Tyvaso DPI is expected to provide a major advancement in the delivery of inhaled treprostinil for PAH and PH-ILD patients."